Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exalgo in Chronic Osteoarthritis Pain
NCT00631319Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Feb 2008
- Primary completion
- Apr 2009
01
Overview
Phase 3, randomised, double-blind trial in osteoarthritis (OA) comparing OROS Hydromorphone with Placebo (2 arms). Primary endpoint: Numeric Rating Scale Pain Intensity at 12 weeks. Started Feb 2008; status: completed.
02
Drugs
hydromorphone
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00631319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00631319.